Figure 2From: A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (tifacogin) in patients with severe community-acquired pneumoniaKaplan-Meier survival analysis for clinical evaluation committee community-acquired pneumonia patients in the non-heparin cohort with microorganism identified. P value = 0.02.Back to article page